Venture Life Group PLC AGM Statement (7113O)
03 Giugno 2020 - 8:00AM
UK Regulatory
TIDMVLG
RNS Number : 7113O
Venture Life Group PLC
03 June 2020
3 June 2020
VENTURE LIFE GROUP PLC
("Venture Life" "VLG" or the "Group")
AGM Statement
Venture Life (AIM: VLG), a leader in developing, manufacturing
and commercialising products for the international self-care
market, will hold its Annual General meeting ("AGM") this morning
as a closed meeting. At the meeting, the Group's CEO, Jerry
Randall, will make the following statement:
"Firstly, on behalf of the Board, I must pay tribute to all our
incredible employees during the unprecedented challenges that have
arisen as a result of COVID-19. Our manufacturing facility in
northern Italy has worked tirelessly to maintain our business, our
production and supply our customers with minimum disruption. Our
commercial team has demonstrated great agility and a strong
entrepreneurial spirit, in quickly responding to market demand for
sanitising gel, and securing new partnership agreements within a
matter of weeks.
As outlined on 27(th) April 2020, we announced the signing of an
exclusive EUR168 million agreement with our existing Chinese
partner for a number of the Group's products, including Dentyl,
with orders in excess of EUR7 million for delivery in 2020.
With a robust long-term order book, a strong balance sheet and
new commercial opportunities, we look forward to updating the
market on our progress as the year progresses.
The Board would like to thank shareholders for their
co-operation and understanding during these challenging and
extraordinary times."
Venture Life's AGM is being held at 10.30 a.m. this morning as a
closed meeting in light of the public health concerns surrounding
the COVID-19 pandemic.
For further information, please contact:
Venture Life Group PLC +44 (0) 1344 578004
Jerry Randall, Chief Executive Officer
Andrew Waters, Chief Financial Officer
+44 (0) 20 7397
Cenkos Securities plc (Nomad and Broker) 8900
Stephen Keys / Mark Connelly / Cameron MacRitchie
(Corporate Finance)
Russell Kerr / Michael Johnson (Sales)
About Venture Life ( www.venture-life.com )
Venture Life is an international consumer self-care company
focused on developing, manufacturing and commercialising products
for the global self-care market. With operations in the UK, The
Netherlands and Italy, the Group's product portfolio includes some
key products such as the UltraDEX and Dentyl oral care product
ranges, food supplements for maintaining brain function, medical
devices for women's intimate healthcare, fungal infections and
proctology, and dermo-cosmetics for addressing the signs of
ageing.
The products, which are typically recommended by pharmacists or
healthcare practitioners, are available primarily through
pharmacies and grocery multiples. In the UK and The Netherlands,
these are supplied direct by the company to retailers, elsewhere
they are supplied by the Group's international distribution
partners.
Through its Development & Manufacturing business in Italy,
Biokosmes, the Group also provides development and manufacturing
services to companies for consumer healthcare products, primarily
medical devices.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
AGMUUAURRRUNRAR
(END) Dow Jones Newswires
June 03, 2020 02:00 ET (06:00 GMT)
Grafico Azioni Venture Life (LSE:VLG)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Venture Life (LSE:VLG)
Storico
Da Apr 2023 a Apr 2024